MXCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MXCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. MaxCyte's Tax Expense for the three months ended in Sep. 2024 was $0.00 Mil. MaxCyte's Pre-Tax Income for the three months ended in Sep. 2024 was $-11.56 Mil. Therefore, MaxCyte's Tax Rate % for the quarter that ended in Sep. 2024 was 0.00%.
The historical data trend for MaxCyte's Tax Rate % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MaxCyte Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Tax Rate % | Get a 7-Day Free Trial | - | - | - | - | - |
MaxCyte Quarterly Data | ||||||||||||||||||||
Jun19 | Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Tax Rate % | Get a 7-Day Free Trial | - | - | - | - | - |
Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.
MaxCyte's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as
Tax Rate % | = | Tax Expense (A: Dec. 2023 ) | / | Pre-Tax Income (A: Dec. 2023 ) |
= | 0 | / | -37.923 | |
= | 0.00 % |
MaxCyte's Tax Rate % for the quarter that ended in Sep. 2024 is calculated as
Tax Rate % | = | Tax Expense (Q: Sep. 2024 ) | / | Pre-Tax Income (Q: Sep. 2024 ) |
= | 0 | / | -11.557 | |
= | 0.00 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of MaxCyte's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.
Stanley C Erck | director | 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878 |
John Joseph Johnston | director | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Thomas M. Ross | officer: EVP, Global Sales | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Maher Masoud | officer: EVP and General Counsel | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Douglas Doerfler | director, officer: President and CEO | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Richard Douglas | director | ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
Douglas J Swirsky | officer: Chief Financial Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850 |
Patrick J Balthrop | director | C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850 |
Casdin Partners Master Fund, L.p. | 10 percent owner | WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001 |
Cenk Sumen | officer: Chief Scientific Officer | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Amanda Louise Murphy | officer: Chief Financial Officer | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Ron Holtz | officer: SVP and CAO | C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
Yasir B. Al-wakeel | director | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Art Mandell | director | C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878 |
William W Brooke | director | 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203 |
From GuruFocus
By Marketwired • 10-31-2024
By GuruFocus News • 11-07-2024
By Marketwired • 09-05-2024
By GuruFocus News • 11-14-2024
By GuruFocus News • 11-07-2024
By GuruFocus Research • 06-11-2024
By GuruFocus Research • 08-06-2024
By Marketwired • 09-16-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 04-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.